Document is current
Any future updates will be listed below
-
Authors
Al-Jumaan, Mohammed
Chu, Hoyin
Alsulaiman, Abdullah
Camp, Sabrina Y.
Han, Seunghun
Gillani, Riaz
Al Marzooq, Yousef
Almulhim, Fatmah
Vatte, Chittibabu
Al Nemer, Areej
Almuhanna, Afnan
Van Allen, Eliezer M.
Al-Ali, Amein
AlDubayan, Saud H. https://orcid.org/0000-0001-9062-3399
-
Funding
Funding for this research was provided by:
King Abdulaziz City for Science and Technology (#12-MED2226-46, #11-MED2101-46)
U.S. Department of Defense (W81XWH-21-1-0084, PC200150, KC210042/W81XWH-22-1-0455)
- License Information
-
More Information
Article History
Received: 4 May 2023
Accepted: 9 August 2023
First Online: 1 September 2023
Declarations
:
: This study was conducted under the following IRB protocol (IAU-IRB#2019-01-109). All individuals in this study consented to institutional review board-approved protocols that allowed for comprehensive genetic analysis of germline samples. This study conforms to the Declaration of Helsinki.
: Not applicable.
: E.M.V.A. holds consulting roles with Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Riva Therapeutics and Serinus Bio; he receives research support from Novartis, Bristol-Myers Squibb and Sanofi; he has equity in Tango Therapeutics, Genome Medical, Genomic Life, Syapse, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics and Serinus Bio; he has filed institutional patents on chromatin mutations, immunotherapy response, and methods for clinical interpretation. R.G. has equity in Google, Microsoft, Amazon, Apple, Moderna, Pfizer, and Vertex Pharmaceuticals. The other authors declare that they have no competing interests.
